HALOZYME THERAPEUTICS, INC. (HALO) Stock Profile — Insider Trades & Financials

Smart-Money SignalNeutral · 47/100— Insiders are net sellers over 90 days (-$4.4M, 20 sales vs 0 buys)

Revenue$481.0M

Net Income$229.9M

EPS$3.11

Market Cap$12.7B

Price Performance

Historical data including institutional events

Company Profile

Helen Torley

CEO & Executive Director

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.

Founded: 1998
Employees: 136
Headquarters: SAN DIEGO, CA, United States
Website: www.halozyme.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Smart-Money SignalNeutral · 47/100— Insiders are net sellers over 90 days (-$4.4M, 20 sales vs 0 buys)

Revenue$481.0M

Net Income$229.9M

EPS$3.11

Market Cap$12.7B

Price Performance

Historical data including institutional events

Company Profile

Helen Torley

CEO & Executive Director

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.

Founded: 1998
Employees: 136
Headquarters: SAN DIEGO, CA, United States
Website: www.halozyme.com

Peer ComparisonRevenue ($B)

▾

Smart-Money Signal

90-DAY POSTURE

47/ 100

NEUTRAL

Insiders are net sellers over 90 days (-$4.4M, 20 sales vs 0 buys). Smart-money posture is balanced.

Insider flow · 90d-$4.4M

Congress flow · 90dno activity

10b5-1 share100% planned

Cluster selling3 officers

Price vs 52w96% of high

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER SELLHelen Torley (PRESIDENT AND CEO) SELL HALOOct 6, 2026

INSIDER EXERCISE / CONVERSIONHelen Torley (PRESIDENT AND CEO) EXERCISE / CONVERSION HALOOct 6, 2026

INSIDER SELLHelen Torley (PRESIDENT AND CEO) SELL HALOOct 6, 2026

INSIDER SELLHelen Torley (PRESIDENT AND CEO) SELL HALOOct 7, 2026

INSIDER EXERCISE / CONVERSIONHelen Torley (PRESIDENT AND CEO) EXERCISE / CONVERSION HALOOct 7, 2026

INSIDER SELLHelen Torley (PRESIDENT AND CEO) SELL HALOOct 7, 2026

INSIDER SELLHelen Torley (PRESIDENT AND CEO) SELL HALOOct 8, 2026

INSIDER EXERCISE / CONVERSIONHelen Torley (PRESIDENT AND CEO) EXERCISE / CONVERSION HALOOct 8, 2026

⚡

Core Efficiency

ROE?

160.17%

ROA?

8.92%

D/E Ratio?

16.96

Op. Margin?

59.80%

📊

Profitability Ratios

Net Margin?

47.80%

Current Ratio?

2.71

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 8, 2026 (in 26 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 8, 2026

Predicted10-Q

Aug 6, 2026

10-QQ2 202637d after period end

May 11, 2026

10-QQ1 202641d after period end

Feb 17, 2026

10-KQ4 202548d after period end

Feb 17, 2026

10-KFY 202548d after period end

Nov 3, 2025

10-QQ3 202534d after period end

Aug 5, 2025

10-QQ2 202536d after period end

May 6, 2025

10-QQ1 202536d after period end

Feb 18, 2025

10-KQ4 202449d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-06

SEC Metadata

2mo ago

Latest filing: 2026-08-06

Loading company sections...

HALOZYME THERAPEUTICS, INC.

Price Performance

Company Profile

HALOZYME THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

HALOZYME THERAPEUTICS, INC.

Price Performance

Company Profile

The morning brief, before the bell.

HALOZYME THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Recent Congress Trades